Volker Schirrmacher

Quo vadis cancer therapy ?

Fascinating discoveries of the last 60 years

• Broschiertes Buch

Produktbeschreibung

Fascinating discoveries have been made in the last 60 years in cancer research. Yet, these discoveries have not changed the main methods of standard cancer treatment. Surgery, radiotherapy and chemotherapy were developed in the first half of the 20th century. At this time nothing was known about the biology of cancer metastasis and about the role of the immune system in the fight against cancer. This book is a plea for an update of cancer treatment by including biology-based treatments, such as immunotherapy and oncolytic virotherapy. These treatments have a higher tumor selectivety and lower side effects than radio-or chemotherapy. In addition they can induce long-lasting effects which are based on cancer-specific immunological memory. We now know that epigenetic mechanisms allow tumors to develop therapy-resistant variants. Therefore, efficacy of future cancer therapy could be improved by targeting cancer-associated epigenetic mechanisms. The tumor microenvironment represents an important support system for cancer growth, invasion and metastasis. Future strategies targeting the tumor microenvironment are considered as promising. The book addresses all people concerned with cancer

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 360
• Erscheinungstermin: 5. Dezember 2017
• Englisch
• Abmessung: 220mm x 150mm x 22mm
• Gewicht: 495g
• ISBN-13: 9786202055451
• ISBN-10: 6202055456
• Artikelnr.: 50315190

Autorenporträt

Volker Schirrmacher, PhD, Prof: Studied Biochemistry at University Tübingen (Germany), PhD in Immunology at University Cologne (Germany), Prof Immunology at University Heidelberg (Germany). 1976-2008 Head of Division Cellular Immunology at the German Cancer Research Center, Heidelberg. 2009-present Head of Tumor Immunology at IOZK, Cologne.